Holly C. Hagan, PhD, MPH

Clinical Assistant Professor, Epidemiology

Contact Information
National Development and Research Institutes, Inc
Center for Drug Use and HIV Research
71 West 23rd, 8th Floor
New York City, NY 10010
http://www.ndri.org/ctrs/cduhr.html
holly.hagan@ndri.org

Research Interests
Infectious disease consequences of injection drug use; particularly the etiology, epidemiology and prevention of blood borne viral infections such as HIV and hepatitis C

Education
PhD, Epidemiology, University of Washington 1997
MPH, Biostatistics, University of Massachusetts 1987

Selected Publications
Hagan H, Des Jarlais DC, Stern R, Lelutiu-Weinberger C, Scheinmann R, Strauss S, Flom P. HCV Synthesis Project: Preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy 2007, in press.

Hagan, H., Latka, M. H., Campbell, J. V., Golub, E. T., Garfein, R. S., Thomas, D. A., Kapadia, F., Strathdee, S. A., & the Study to Reduce Intravenous Exposures Project Team. Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Clin Infect Dis, 2006;42: 669-672.

Hagan H, Thiede H, Des Jarlais DC. HIV/HCV Co-Infection in Drug Users: Risk Behavior and Prevention. AIDS, 2006;19 (Supplement 3), S199-S207.

Hagan H, Thiede H, Des Jarlais DC. Time to HCV seroconversion in a cohort of Seattle IDUs. Epidemiology 2004; 15: 543-549.

Hagan H. The relevance of attributable risk measures to HIV prevention planning. AIDS 2003;17:911-3.